Supply Center USA offered unapproved Similasan and Boiron eye drug products for sale online.
What happened
FDA reviewed Supply Center USA's website in May 2025 and observed that it offered Similasan eye relief products and Boiron Optique 1 Eye Irritation Relief for sale in the United States. FDA determined these ophthalmic products are unapproved new drugs and that no FDA-approved applications are in effect for them. FDA also said they are not generally recognized as safe and effective for their labeled uses.
What FDA found
The products are not generally recognized as safe and effective for their labeled uses, so they are new drugs under the law.
section 201(p) of the FD&C Act, 21 U.S.C. 321(p)No FDA-approved application is in effect for these products, so they are unapproved new drugs.
section 505(a) of the FD&C Act, 21 U.S.C. 355(a)Introducing or delivering these products for introduction into interstate commerce violates the FD&C Act.
sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)Website claims show the products are intended to relieve or treat eye symptoms, making them drugs.
section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
What FDA wants
FDA asks Supply Center USA to notify it in writing within 15 working days of the steps taken to correct the violations, including preventive steps and supporting documents. If the firm believes there is no violation, it must include its reasoning and supporting information; if corrective action cannot be completed in time, it must state why and when it will be completed.
Who should pay attention
- retailers and online marketplaces selling Similasan or Boiron eye products
- distributors and brands of homeopathic ophthalmic products
- consumers using eye drops labeled homeopathic
This is a summary. Read the original letter on fda.gov.